3-(2-甲基-1,3-二氧杂烷-2-基)苯甲醛 | 132100-31-3

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-甲基-1,3-二氧杂烷-2-基)苯甲醛
• 英文名称: 2-(3-formylphenyl)-2-methyl-1,3-dioxolane
• 英文别名: 3-(2-methyl-[1,3]dioxolan-2-yl)benzaldehyde；Benzaldehyde, 3-(2-methyl-1,3-dioxolan-2-yl)-；3-(2-methyl-1,3-dioxolan-2-yl)benzaldehyde
• CAS: 132100-31-3
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: NSMDBQYWQPQJBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-甲基-1,3-二氧杂烷-2-基)苯甲醛 在 盐酸 、 manganese(IV) oxide 、 正丁基锂 、 四甲基乙二胺 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 3.0h， 生成 4-(3-acetylbenzoyl)-3-amino-5-ethyl-6-methyl-1H-pyridin-2-one
  参考文献：
  名称：

  4-Benzyl- and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones, a New Family of Potent Anti-HIV Agents:  Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains

  摘要：

  The 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 13 and 14 are representatives of a new class of highly potent non nucleoside type inhibitors of HIV-1 reverse transcriptase. To conduct SAR studies on these two lead compounds, 102 new analogues were prepared. Thirty-three compounds displayed nanomolar range activity in vitro against wild-type HIV-1, and among these, 18 were active against the 103N, Y181C, and Y188L mutant strains with IC50 values inferior to 1 muM. Evaluation of this group of analogues against an additional eight single [100I, 101E, 106A, 138K, 179E, 190A, 190S, 227C] and four double HIV mutant strains [100I + 103N, 101E + 103N, 103N + 181C, and 227L + 106A], which are often present in HIV infected patients, permitted the selection of eight compounds, 17x, 18b, 18c, 18f, 18g, 27, 30, and 42, which are globally more active than the lead molecules 13/14, emivirine and the currently used NNRTI, nevirapine. Further comparison of the 3'-CN-substituted benzoylpyridinone compound 18c, and the corresponding 3'-acrylonitrile-substituted analogue 30, to efavirenz, the reference molecule in anti-HIV therapy today, revealed that the pyridinone analogues displayed a superior inhibition profile in the in vitro cellular assay system. These results form a solid basis for continued optimization of the pyridinone series.

  DOI：

  10.1021/jm0407658
• 作为产物：
  描述：

  3-(2-methyl-1,3-dioxolan-2-yl)benzonitrile 在 二异丁基氢化铝 、 盐酸 、 水 作用下， 以 二氯甲烷 、 甲苯 、 甲醇 为溶剂， 反应 4.0h， 以85%的产率得到3-(2-甲基-1,3-二氧杂烷-2-基)苯甲醛
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Constrained meta-Substituted Phenyl Propanoic Acids as Peroxisome Proliferator-Activated Receptor α and γ Dual Agonists

  摘要：

  In an effort to develop dual PPAR alpha/gamma activators with improved therapeutic efficacy, a series of diaryl alpha-ethoxy propanoic acid compounds comprising two aryl groups linked by rigid oxime ether or isoxazoline ring were designed and synthesized and their biological activities were examined. Most of the compounds possessing an oxime ether linker were more potent PPAR gamma activators than the lead PPAR alpha/gamma dual agonist, tesaglitazar in vitro. Compound 18, one of the derivatives with an oxime ether linker, was found to selectively transactivate PPAR gamma (EC(50) = 0.028 mu M) over PPAR alpha (EC(50) = 7.22 mu M) in vitro and lower blood glucose in db/db mice more than muraglitazar after oral treatment for 11 days.

  DOI：

  10.1021/jm8003416

文献信息

• AMINOPYRAZOLE DERIVATIVES
  申请人：Bur Daniel

  公开号：US20110034516A1

  公开（公告）日：2011-02-10

  The invention relates to aminopyrazole derivatives of formula (I), wherein A, E, R 1 and R 2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  这项发明涉及公式（I）的氨基吡唑衍生物， 其中A、E、R1和R2如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。
• [EN] COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UNE INFECTION À ARÉNAVIRUS
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2016160677A1

  公开（公告）日：2016-10-06

  The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.

  本发明涉及使用哌嗪酮类化合物抑制人类、其他哺乳动物或细胞培养中的病毒感染，用于治疗拉沙病、玻利维亚病、阿根廷病、委内瑞拉病、巴西病、查帕雷病和卢霍出血热等病毒感染的方法，用于抑制病毒复制的方法，用于减少病毒数量的方法，以及可用于这些方法的组合物。
• Synthesis of Novel Oximes of 2-Aryl-6-methoxy-3,4-dihydronaphthalene and Their Evaluation as Inhibitors of 17α-Hydroxylase-C17,20-Lyase (P450 17)
  作者：Yan Zhuang、Rolf W. Hartmann

  DOI：10.1002/(sici)1521-4184(199801)331:1<36::aid-ardp36>3.0.co;2-0

  日期：1998.1

  The synthesis and biological evaluation of oximes of 2‐aryl‐6‐methoxy‐3,4‐dihydronaphthalene (7a, 7b, 14a, 14b) as nonsteroidal inhibitors of 17α‐hydroxylase‐C17,20‐lyase (P450 17, CYP 17) is described. The target compounds were synthesized and identified by 1H NMR and MS. The preparation of the key intermediates 5a and 5b was accomplished by coupling 4a and 4b with 1 (2‐hydroxy‐6‐methoxy‐3,4‐dihy

  2-芳基-6-甲氧基-3,4-二氢萘（7a、7b、14a、14b）肟作为17α-羟化酶-C17,20-裂解酶（P450 17，CYP 17）的非甾体抑制剂的合成和生物学评价被描述。目标化合物经 1H NMR 和 MS 合成和鉴定。关键中间体5a和5b的制备是通过使用钯配合物Pd（PPh3）4作为催化剂，将4a和4b与1（2-羟基-6-甲氧基-3,4-二氢萘-2-三氟甲磺酸盐）偶联来完成的。5a 和 5b 在室温下在 THF-HCl 溶液中水解得到相应的酮化合物 6a 和 6b。其他重要的中间体——取代的 (E)-2-亚甲基-1-四氢萘酮 10a 和 10b——是通过 1-四氢萘酮与相应的芳香醛（9a 和 9b）缩合获得的。加氢 (H2)，然后还原 (NaBH4)，随后的水解和消除导致酮化合物 13a 和 13b。标题化合物，即肟 7a、7b 和 14a、14b 是由盐酸羟胺与相应的酮化合物
• Vitamin D analogues
  申请人：Galderma Research & Development S.N.C.

  公开号：US06689922B1

  公开（公告）日：2004-02-10

  The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.

  这项发明涉及具有以下公式的新型双芳香化合物：这些化合物是维生素D的类似物，涉及它们的制备过程，以及它们在人类或兽医药学中的药用组合物中的使用，特别是在皮肤病学、癌症治疗、自身免疫疾病治疗以及器官或组织移植中。还包括化妆品组合物和使用方法。
• [EN] AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS<br/>[FR] DÉRIVÉS D'AMINOTRIAZOLE COMME AGONISTES D'ALX
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009077990A1

  公开（公告）日：2009-06-25

  The invention relates to aminotriazole derivatives of formula (I), wherein A, E, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds. The compounds are useful for the prevention or treatment of diseases, which respond to the modulation of the ALX receptor such as inflammatory diseases.

  这项发明涉及公式(I)的氨基三唑衍生物，其中A、E、R1和R2如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。这些化合物对于预防或治疗对ALX受体调节产生反应的疾病，如炎症性疾病，是有用的。